BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7683228)

  • 1. Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology.
    Hagemeister FB
    Leuk Lymphoma; 1993; 10 Suppl():21-7. PubMed ID: 7683228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
    Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
    Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
    Engelhard M; Meusers P; Brittinger G; Brack N; Dornoff W; Enne W; Gassmann W; Gerhartz H; Hallek M; Heise J
    Ann Oncol; 1991 Feb; 2 Suppl 2():177-80. PubMed ID: 1710919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
    Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
    J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
    Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
    J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
    J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients.
    Todeschini G; Ambrosetti A; Meneghini V; Pizzolo G; Menestrina F; Chilosi M; Benedetti F; Veneri D; Cetto GL; Perona G
    J Clin Oncol; 1990 May; 8(5):804-8. PubMed ID: 1692089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma.
    Nowrousian MR; Meier CR; Schoetensack B; Anders C; Höffken K; Osieka R; Schmidt CG
    Acta Oncol; 1989; 28(4):495-500. PubMed ID: 2477048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response-oriented therapy with CHOP and VIM-Bleo in high-grade malignant non-Hodgkin's lymphomas.
    Steinke B; Krüger HU; Kraft H; Heim ME; Günther E; Arnold H; Busch FW
    Blut; 1988 Jun; 56(6):269-71. PubMed ID: 2454690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
    Teodorovic I; Pittaluga S; Kluin-Nelemans JC; Meerwaldt JH; Hagenbeek A; van Glabbeke M; Somers R; Bijnens L; Noordijk EM; Peeters CD
    J Clin Oncol; 1995 Nov; 13(11):2819-26. PubMed ID: 7595744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
    Fridrik MA; Hausmaninger H; Linkesch W; Stöger M; Sill H; Neubauer M; Seewann HL; Klocker J; Haidinger R; Schiller L; Pont J; Raudaschl G; Falk M; Radaszkiewicz T
    J Clin Oncol; 1996 Jan; 14(1):227-32. PubMed ID: 8558202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in chemotherapy for large cell lymphoma.
    Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma.
    De Lord C; Newland AC; Linch DC; Vaughan Hudson B; Vaughan Hudson G
    Hematol Oncol; 1992; 10(2):81-6. PubMed ID: 1592365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy.
    Gerhartz HH; Thiel E; Brittinger G; Dörken B; Engelhard M; Engert W; Enne W; Fuchs R; Hagen-Aukamp CH; Huhn D
    Blut; 1988 Mar; 56(3):139-42. PubMed ID: 2451551
    [No Abstract]   [Full Text] [Related]  

  • 20. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.